These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29746266)

  • 1. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
    Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST
    Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study.
    Gathe JC; Hardwicke RL; Garcia F; Weinheimer S; Lewis ST; Cash RB
    J Acquir Immune Defic Syndr; 2021 Apr; 86(4):482-489. PubMed ID: 33427765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based strategies in HIV therapy.
    Kufel WD
    Int J Antimicrob Agents; 2020 Dec; 56(6):106186. PubMed ID: 33045349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibalizumab: First Global Approval.
    Markham A
    Drugs; 2018 May; 78(7):781-785. PubMed ID: 29675744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
    Bruno CJ; Jacobson JM
    J Antimicrob Chemother; 2010 Sep; 65(9):1839-41. PubMed ID: 20639524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection.
    Chahine EB; Durham SH
    Ann Pharmacother; 2021 Feb; 55(2):230-239. PubMed ID: 32659101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
    Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostemsavir: a new CD4 attachment inhibitor.
    Cahn P; Fink V; Patterson P
    Curr Opin HIV AIDS; 2018 Jul; 13(4):341-345. PubMed ID: 29771694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep.
    Morrow T
    Manag Care; 2018 Jun; 27(6):31-33. PubMed ID: 29989910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):68-69. PubMed ID: 29667947
    [No Abstract]   [Full Text] [Related]  

  • 17. Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
    Bachelard A; Le Hingrat Q; Ferré VM; Lê M; Peytavin G; Damond F; Charpentier C; Fremont Goudot G; Goupil de Bouille J; Lariven S; Delobel P; Yazdanpanah Y; Descamps D; Matheron S; Ghosn J;
    Clin Infect Dis; 2024 Apr; 78(4):1005-1010. PubMed ID: 38630945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
    Fischl MA
    AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.
    Brogan AJ; Talbird SE; Davis AE; La EM; Kumar PN
    Pharmacoeconomics; 2021 Apr; 39(4):421-432. PubMed ID: 33532919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.
    Fessel WJ; Anderson B; Follansbee SE; Winters MA; Lewis ST; Weinheimer SP; Petropoulos CJ; Shafer RW
    Antiviral Res; 2011 Dec; 92(3):484-7. PubMed ID: 22001594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.